Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

Despite recent advances, chemoimmunotherapy remains a standard for fit previously untreated chronic lymphocytic leukaemia patients. Lenalidomide had activity in early monotherapy trials, but tumour lysis and flare proved major obstacles in its development. We combined lenalidomide in increasing dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Egle, Alexander, Steurer, Michael, Melchardt, Thomas, Weiss, Lukas, Gassner, Franz Josef, Zaborsky, Nadja, Geisberger, Roland, Catakovic, Kemal, Hartmann, Tanja Nicole, Pleyer, Lisa, Voskova, Daniela, Thaler, Josef, Lang, Alois, Girschikofsky, Michael, Petzer, Andreas, Greil, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097797/
https://www.ncbi.nlm.nih.gov/pubmed/29862437
http://dx.doi.org/10.1007/s00277-018-3380-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097797/
https://www.ncbi.nlm.nih.gov/pubmed/29862437
http://dx.doi.org/10.1007/s00277-018-3380-z

Ejemplares similares